Conserved Stress-protective Activity between Prion Protein and Shadoo*

Received for publication, September 15, 2010, and in revised form, January 5, 2011 Published, JBC Papers in Press, January 21, 2011, DOI 10.1074/jbc.M110.185470

Vignesh Sakhivelu1, Ralf P. Seidel5, Konstanze F. Winklhofer1, and Jörg Tatzelt1,2

From the 4Neurobiochemistry, Adolf-Butenandt-Institute, Ludwig-Maximilians-University Munich, D-80336 Munich and the 5Max-Planck-Institute of Molecular Physiology, 44227 Dortmund, Germany

Shadoo (Sho) is a neuronally expressed glycoprotein of unknown function. Although there is no overall sequence homology to the cellular prion protein (PrPc), both proteins contain a highly conserved internal hydrophobic domain (HD) and are tethered to the outer leaflet of the plasma membrane via a C-terminal glycosylphosphatidylinositol anchor. A previous study revealed that Sho can reduce toxicity of a PrP mutant devoid of the HD (PrPΔHD). We have now studied the stress-protective activity of Sho in detail and identified domains involved in this activity. Like PrPc, Sho protects cells against physiological stressors such as the excitotoxin glutamate. Moreover, both PrPc and Sho required the N-terminal domain for this activity; the stress-protective capacity of PrPΔN as well as ShoΔN was significantly impaired. In both proteins, the HD promoted homodimer formation; however, deletion of the HD had different effects. Although ShoΔHD lost its stress-protective activity, PrPΔHD acquired a neurotoxic potential. Finally, we could show that the N-terminal domain of PrPc could be functionally replaced by that of Sho, suggesting a similar function of the N termini of Sho and PrPc. Our study reveals a conserved physiological activity between PrPc and Sho to protect cells from stress-induced toxicity and suggests that Sho and PrPc might act on similar signaling pathways.

Prion diseases in humans and other mammals are characterized by a conformational transition of the cellular prion protein (PrPc)3 into an aberrantly folded isoform, designated scrapie prion protein (PrPSc). PrPSc can form amyloid plaques in the diseased brain and is the major constituent of infectious prions (reviewed in Refs. 1–4). Biogenesis of PrPc is essential for the propagation of infectious prions (5). Moreover, neuronal expression of PrPc seems to be required to mediate neurotoxic effects of scrapie prions (6–9).

Structural studies with recombinantly expressed PrP revealed a large flexibly disordered N-terminal region, containing an octarepeat region, and a structured C-terminal domain (aa 121–231). This autonomously folding domain contains three α-helical regions and a short two-stranded β-sheet (10–12). The C-terminal domain is characterized by extensive co- and post-translational modifications, including two N-linked glycans with complex structure, a disulfide bridge, and a C-terminal glycosylphosphatidylinositol (GPI) anchor (reviewed in Ref. 13). Interestingly, the octarepeat region in the N-terminal domain as well as the C-terminal GPI anchor are dispensable for the generation of infectious prions (8, 14) but are required for the stress-protective activity of PrPc (9, 15).

Although in the majority of prion diseases there is a correlation between the accumulation of PrPSc, formation of infectious prions, and neurodegeneration, there are some interesting exceptions. Transgenic mouse models revealed that several PrP mutants can induce neuronal cell death in the absence of infectious prion propagation (reviewed in Ref. 16). From one class of PrP mutants, it emerged that PrPc can acquire a neurotoxic potential by deleting the internal HD (17–19). Similarly to PrPc, PrPΔHD is complex glycosylated and linked to the plasma membrane via a GPI anchor (20). Moreover, expression of PrPc can completely prevent the neurotoxic activity of PrPΔHD, suggesting that PrPc and PrPΔHD can induce neuroprotective or neurotoxic signaling via binding to the same signal-transducing protein(s) (9, 19). Indeed, numerous studies in transgenic animals and cultured cells are now supporting the idea that the physiological role of PrPc is to protect neuronal cells against stress-induced cell death (reviewed in Ref. 21).

In the search for homologs/paralogs of PrPc, a new gene was identified termed Sprn, encoding for a protein denoted Shadoo (Sho) (22). Sho is highly conserved from fish to mammals. The sequence homology between Sho and PrP is restricted to the internal hydrophobic domain; however, certain features, such as a N-terminal repeat region and a C-terminal GPI anchor, are conserved, suggesting that Sho and PrP may be functionally related. Experimental evidence for the post-translational modifications and cell surface localization of Sho was first presented for zebrafish Sho (23) and afterward also for mouse Sho (24). Moreover, it was demonstrated that Sho, similarly to PrPc, can prevent neuronal cell death induced by the expression of PrPΔHD mutants (24).
In this study, we analyzed the stress-protective activity of Sho in detail and defined domains required for this activity. Furthermore, the generation of a N-Sho-PrP-C chimeric protein revealed that the N terminus of Sho can restore the stress-protective activity of a PrP mutant devoid of the N-terminal domain (PrPΔN).

**EXPERIMENTAL PROCEDURES**

**Reagents and Antibodies**—All standard chemicals and reagents were purchased from Sigma if not otherwise noted. The following antibodies were used: mouse monoclonal anti-PrP 3F4 antibody (25), mouse monoclonal anti-V5 tag antibody (Invitrogen), mouse monoclonal anti-HA tag antibody (Covance), anti-active caspase-3 polyclonal antibody (Promega), Cy3-conjugated anti-rabbit IgG antibody (Dianova), and Cy3-conjugated anti-mouse IgG antibody (Dianova). For the generation of a rabbit polyclonal anti-Sho antibody, recombinant human full-length Sho, expressed in and purified from *Escherichia coli*, was used for the immunization of rabbits (Eurogentec, Seraing, Belgium). The mounting medium Mowiol (Calbiochem) was supplemented with 4',6-diamidino-2-phenylindole (DAPI).

**Plasmid Construction**—The cloning of PrP, PrPΔN (Δ28–89), PrPΔHD (Δ113–133), and PrP5131C was described previously (20, 26, 27). The human Sho gene was prepared by ligation-based strategy for chemical gene synthesis using the Sloning building block technology (28) (Sloning, Puchheim, Germany) and cloned into a pcDNA 3.1/ZeO (+). A V5 tag (5’-GAT AAA CCG ATA CCG AAC CCG CTC CTC GGT CTC TGC TAC CCA TAC GATT GTT CCA GAT CAC GCT-3’) or HA tag (5’-TAC CCA TAC GAT GTT CCA GAT CAC GCT-3’) was inserted between amino acids 124 and 125. Sho was used as a template to introduce the following deletions and mutations by standard PCR cloning techniques: ShoΔN (aa 30–56 deleted), ShoΔHD (aa 68–89 deleted), Sho587C (serine at aa 87 replaced with cysteine), and ShoΔN587C (aa 30–56 deleted; serine at aa 87 replaced with cysteine). All amino acid numbers refer to the human Shadoo sequence (GenBank™ association number NM_001012508). The chimeric N-Sho-PrP-C (Sho 1–63 and PrP 89–254) was generated by PCR and cloned into pcDNA 3.1/ZeO (+) vector.

**Cell Culture, Transfection, Protein Deglycosylation, Phospholipase C, Tunicamycin, Brefeldin A Treatment, and Western Blotting**—Human neuroblastoma cells (SH-SY5Y) were cultured as described earlier (20). Cultured cells were transfected with Lipofectamine Plus (Invitrogen) according to the manufacturer’s instruction. After 24 h, cells were washed with cold PBS, scraped off the plate, pelleted, and lysed in cold detergent buffer (0.5% Triton X–100, 0.5% sodium deoxycholate in PBS). Endo H (New England Biolabs) and PNGase F (Roche Applied Science) digestions were done according to the manufacturer’s instruction. To inhibit N-linked glycosylation or transport to the plasma membrane, transfected cells were grown in the presence of tunicamycin (0.5 μg/ml) or brefeldin A (1 μg/ml), respectively. 24 h later, cells were analyzed. For phosphatidylinositol-specific phospholipase C (PIPLC) treatment, cells were washed twice with cold PBS. PIPLC (1 units/ml) was added to the cells for 3 h at 4 °C. The medium was collected, and cells were washed twice with cold PBS and lysed in cold detergent buffer. Proteins present in the medium were precipitated by trichloroacetic acid (TCA), boiled in Laemmli sample buffer, and analyzed by Western blotting as described earlier (29).

**Apoptosis Assay**—As described earlier (27), SH-SY5Y cells were grown on coverslips. 24 h after transfection, the cells were incubated with glutamate (500 μM) for 3 h. The cells were then fixed, and activated caspase-3 was detected by indirect immunofluorescence using an anti-active caspase-3 antibody. To detect cells undergoing apoptosis, the number of activated caspase-3-positive cells out of at least 1100 transfected cells was determined using a Zeiss Axioskop 2 Plus microscope (Carl Zeiss, Göttingen, Germany). Quantifications were based on triplicates of at least three independent experiments.

**Co-immunoprecipitation**—To analyze formation of a mixed PrP/Sho dimer, SH-SY5Y cells were co-transfected with PrP5131C and Sho587C. At 24 h after transfection, the cells were harvested and lysed in ice-cold detergent lysis buffer (0.5% Triton X–100, 0.5% sodium deoxycholate in PBS) supplemented with protease inhibitors. Precleared lysates were incubated with αV5 antibody overnight at 4 °C. The immunocomplex was precipitated with protein A-Sepharose beads and analyzed by Western blotting. To analyze formation of Sho trans-dimers, separate dishes of SH-SY5Y cells were transfected with either Sho587C-V5 or Sho587C-HA. 3 h after transfection, cells were extensively washed, trypsinized, mixed together, and seeded in one cell culture dish. 24 h later, the cells were harvested and analyzed as described above.

**Indirect Immunofluorescence Microscopy**—Transfected SH-SY5Y cells were grown on glass coverslips and fixed 24 h after transfection with 3% paraformaldehyde for 20 min. Fixed cells were incubated with primary antibody for 45 min at 37 °C in PBS containing 1% BSA. After extensive washing with cold PBS, incubation with the Cy3-conjugated secondary antibody followed at 37 °C for 30 min. Cells were mounted onto glass slides and examined by fluorescence microscopy.

**Statistical Analysis**—Data were expressed as means ± S.E. Statistical analysis was carried out using Student’s *t* test. *p* values are as follows: *, *p* < 0.05, **, *p* < 0.005, ***, *p* < 0.0005.

**RESULTS**

Sho Mutants Devoid of the N-terminal Domain or the Internal Hydrophobic Domain Are Complex Glycosylated and Targeted to the Outer Leaflet of the Plasma Membrane via a GPI Anchor—In a previous study, we have shown that zebrafish Sho expressed in mammalian cells is a complex glycosylated, GPI-anchored protein present at the outer leaflet of the plasma membrane (23). For a functional characterization of mammalian Sho, we cloned the human homolog and several mutants as outlined in Fig. 1A. The design of the Sho mutants was based on PrP mutants that have been characterized previously. PrPΔN, a mutant lacking large parts of the intrinsically disordered N terminus (Δaa 27–89), can promote propagation of infectious prions (14) but shows an impaired neuroprotective activity (9, 15). PrPΔHD lacks the highly conserved internal hydrophobic domain (Δaa 113–133) and is characterized by a neurotoxic potential that can be blocked by the co-expression of wild type (WT) PrPC (9, 17–19). Importantly, these PrP mutants are
complex glycosylated and targeted to the outer surface of the plasma membrane via a GPI anchor (20).

First, we expressed the different Sho constructs and the corresponding PrP mutants in human SH-SY5Y cells to analyze the co- and post-translational modifications. To evaluate the modification with N-linked glycans, cell lysates were treated with PNGase F to remove all N-linked glycans. The apparent shift in electrophoretic mobility after PNGase F digestion indicated that all constructs are modified with N-linked glycans. The glycans were resistant to Endo H digestion (data not shown), indicating that all constructs are complex glycosylated. SH-SY5Y cells were transiently transfected with the constructs indicated. Total cell lysates were treated with PNGase F (+) or left untreated (−), and PrP or Sho were detected by Western blotting.

To test for a C-terminal GPI anchor, live cells were incubated with PIPLC to release GPI-anchored proteins from the cell surface. Indeed, after PIPLC treatment, the relative amount of the PrP constructs in the cell lysates decreased concomitantly with the appearance of the respective proteins in the cell culture supernatant (Fig. 2A). Similarly, PIPLC treatment reduced the relative amount of the Sho constructs present in the cell lysates. In parallel, Sho and ShoΔN were found in the supernatant of PIPLC-treated cells (Fig. 2A). Curiously, we never detected significant amounts of ShoΔHD in the cell culture medium after PIPLC treatment, using neither the V5 nor our newly generated polyclonal anti-Sho antisera. So far, we have not been able to unravel the underlying mechanisms for this phenomenon. However, when we performed indirect immunofluorescence of non-permeabilized cells, we were able to demonstrate localization of all constructs, including ShoΔHD, at the outer surface of the plasma membrane (Fig. 2B). In sum, these data revealed that wild type Sho as well as Sho mutants devoid of the N-terminal domain or the internal HD are complex glycosylated and tethered to the outer leaflet of the plasma membrane via a GPI anchor.

**Sho Protects Cells from Apoptotic Cell Death Induced by Excitotoxic Stress or the Expression of a Neurotoxic PrP Mutant**—To evaluate the stress-protective capacity of Sho, we employed two different stress paradigms, exposition of cells to the excitotoxin glutamate and expression of the neurotoxic PrP mutant PrPΔHD. To identify cells undergoing apoptosis, transiently transfected SH-SY5Y cells were analyzed by indirect immunofluorescence using an antibody specific for activated caspase-3. Please note that SH-SY5Y cells are characterized by low levels of endogenous PrP(8) (Fig. 3A, right panel, pcDNA, 3F4). Consistent with previous findings (9), PrP(8) was able to protect cells against excitotoxic cell death, whereas the deletion of the intrinsically disordered N-terminal domain lead to a loss of this activity (Fig. 3A). Similarly to PrP(8), full-length Sho displayed a stress-protective capacity, which was abolished by the deletion of the N-terminal domain (Fig. 3A). These findings indicate
that deletion of the N-terminal domain of PrP or Sho had similar consequences. However, deletion of the internal HD had distinct effects. As previously documented in transgenic mice and cell culture models (9, 17–19), PrP\textsubscript{H9004} HD acquires a toxic activity (Fig. 3A). Sho\textsubscript{H9004} HD lost its stress-protective activity; however, in contrast to PrP\textsubscript{H9004} HD it did not induce cell death (Fig. 3A).

In the next step, we employed expression of PrP\textsubscript{ΔHD} as a toxic insult. As expected from previous studies, toxic effects of PrP\textsubscript{ΔHD} expression were alleviated by the co-expression of PrP\textsuperscript{C} (Fig. 3B). Corroborating earlier results with primary neurons (24), Sho was also able to suppress toxicity induced by PrP\textsubscript{ΔHD} (Fig. 3B). However, neither PrP\textsubscript{ΔN} nor Sho\textsubscript{ΔN} prevented apoptosis in cells expressing PrP\textsubscript{ΔHD}. Similarly, Sho\textsubscript{ΔHD} could not interfere with the toxic effects of PrP\textsubscript{ΔHD} (Fig. 3B).

The Hydrophobic Domain Mediates Homodimerization of Sho—In a previous study, we could show that the HD mediates dimerization of PrPC and is part of the dimer interface (9). Because the HDs of Sho and PrP are highly homologous (44.4%, Fig. 1B), we tested whether the HD of Sho has a similar activity. To stabilize a possible Sho dimer, we replaced serine 87 with cysteine (Fig. 4A). In case the HD is part of a dimer interface, cysteine 87 could form an intermolecular disulfide bond, which is stable in SDS buffers under non-reducing conditions. Thus, dimer formation can be analyzed by SDS-PAGE followed by Western blotting by preparing protein lysates with sample buffer devoid of reducing agents, such as 2-mercaptoethanol.
The N-terminal Domain of Sho Can Restore Stress-protective Activity of PrPΔN—The functional characterization of Sho mutants presented above revealed a critical role of the N-terminal domain for the stress-protective activity of Sho. Similarly, PrPΔN lacks a stress-protective activity in cell culture and animal models (Fig. 3) (9, 15). To test for the intriguing possibility of a conserved function of the N-terminal domains of PrPC and Sho, we fused the N-terminal domain of Sho to PrPΔN (Fig. 6A). Expression and post-translational modifications of N-ShoPrP-C were similar to that of wild type PrP or wild type Sho; the chimeric protein was complex glycosylated and tethered to the outer leaflet of the plasma membrane via a GPI anchor (Fig. 6, B and C). We then compared the stress-protective activity of N-ShoPrP-C to that of PrPΔN. As described above, we used two different toxic conditions: 1) expression of the neurotoxic PrP mutant PrPΔHD and 2) treatment of cells with the excitotoxin glutamate. Indeed, these experiments revealed that the N-terminal domain of Sho can restore the stress-protective capacity of PrPΔN. Similarly to full-length Sho or full-length PrP, N-ShoPrP-C interfered with apoptotic cell death of SH-SY5Y cells expressing PrPΔHD (Fig. 6D) or exposed to glutamate (Fig. 6E).
Sho is a highly conserved protein found from fish to humans. Although it has no overall sequence homology to PrP, both proteins contain a conserved internal hydrophobic domain and a C-terminal GPI anchor, two elements important for physiological and toxic activities of PrP. Our study presents experimental evidence that Sho and PrP are characterized by a conserved activity to protect cells against stress-induced cell death and suggests that both proteins might act on similar signaling pathways.

The Stress-protective Activity of Sho Is Dependent on the N-terminal Domain and the Internal Hydrophobic Domain—

The first finding of our study was that the stress-protective activity of Sho is not restricted to counteracting the toxic effects of PrPΔHD, an artificial PrP mutant devoid of the internal HD. We employed glutamate as a physiologically relevant stressor to show that Sho can efficiently protect cells against excitotoxin-induced cell death. Deletion mutants revealed that the stress-protective activity of Sho and PrP seems to be dependent on similar domains, in particular the N-terminal and the internal HD. ShoN and ShoΔHD displayed a reduced stress-protective activity but are complex glycosylated and attached to the outer leaflet of the plasma membrane via a GPI anchor, indicating that the impaired activity is not due to incorrect cellular trafficking.

What could be the role of the N-terminal domain and the internal HD in promoting protective signaling? The N-terminal...
domain of PrP is intrinsically disordered, and it has been shown that intrinsically disordered domains are often involved in protein-protein interactions (30). Thus, it would be an attractive idea to assume that the N-terminal domains of PrPC and Sho mediate interaction with a yet unknown co-receptor required for intracellular signal transmission. Interestingly, a circular dichroism analysis of recombinant Sho indicated that the whole protein might be unstructured (24). The HD is the only domain with significant sequence homologies between Sho and PrP<sup>C</sup>. Indeed, the HD promoted dimerization of both Sho and PrP<sup>C</sup> and was part of the dimer interface. In this context, it is worth mentioning that dimerization is a common feature of many cell surface receptors; therefore, it can be speculated that dimer formation is involved in signal transmission of PrP<sup>C</sup>- and Sho-dependent pathways. Notably, formation of both PrP and Sho homodimers is not dependent on N-linked glycosylation and already occurs during transit through the secretory pathway. Similarly, PrP and Sho mutants devoid of the N-terminal

**FIGURE 6.** The N-terminal domain of Sho can functionally replace that of PrP. A, schematic presentation of the chimeric protein N-Sho-PrP<sub>C</sub> (Sho-PrP). ER-SS, endoplasmic reticulum signal sequence; R/RG, arginine- and glycine-rich basic repeats; S-S, disulfide bridge; GPI-SS, glycosylphosphatidylinositol anchor signal sequence; α, α-helical region. CHD, N-linked glycosylation acceptor site. B, Sho-PrP is efficiently expressed in SH-SYSY cells. Cell lysates from transiently transfected cells were analyzed by Western blotting. C, Sho-PrP is complex glycosylated and GPI-anchored. Lysates prepared from transiently transfected SH-SYSY cells were treated with Endo H or PNGase F to analyze N-linked glycosylation. In parallel, transfected cells were incubated at 4 °C for 3 h with PIPLC to release GPI-anchored proteins from the cell surface (PIPLC +) or mock-treated (PIPLC −). Sho-PrP present in the cell culture supernatant was analyzed by Western blotting. D, expression of Sho-PrP interferes with toxic effects of PrPΔHD. SH-SYSY cells were transiently transfected with PrPΔHD or PrPΔHD and the constructs indicated. Cells undergoing apoptosis were analyzed as described in the legend for Fig. 3. The percentage of apoptotic cells among transfected cells is shown. Expression levels were analyzed by immunoblotting (lower panel). E, Sho-PrP protects against stress-induced apoptosis. SH-SYSY cells expressing the constructs indicated were stressed with glutamate (500 μM) for 3 h at 37 °C. Apoptotic cell death was determined as described in the legend for Fig. 3. Expression levels were analyzed by immunoblotting (lower panel). *, p < 0.05, **, p < 0.005, ***, p < 0.0005.
domain are still capable of forming homodimers; however, they have an impaired stress-protective activity.

Distinct Activity of PrPΔHD—Studies in transgenic mice revealed the unexpected finding that PrP can acquire a neurotoxic potential simply by deleting the internal hydrophobic domain (17–19). Importantly, the neurotoxic potential of PrPΔHD is independent of the propagation of infectious prions, a phenomenon also seen for other neurotoxic PrP mutants (reviewed in Ref. 16). Although the underlying mechanisms of PrPΔHD-induced toxicity are still elusive, co-expression of wild type PrPΔC completely prevents toxic effects of PrPΔHD. Based on this intriguing observation, it has been hypothesized that the stress-protective signaling of PrPΔC and the neurotoxic signaling of PrPΔHD are transmitted through a common co-receptor, which remains to be identified (9, 17–19). Interestingly, co-transfection experiments with PrP-deficient cerebellar granule neurons indicated that Sho has a PrPΔC-like activity to alleviate toxic effects of PrPΔHD expression (24). We have been able to recapitulate the toxic activity of PrPΔHD expression in our cell culture model and to demonstrate the protective activity of PrP and Sho against PrPΔHD-induced toxicity. In addition, we could show that ShoΔHD lost its ability to protect against stress-induced cell death; however, ShoΔHD did not acquire a toxic activity, at least not under the experimental conditions tested. Thus, it appears that Sho and PrP share a stress-protective activity; however, the ability to adopt a toxic conformation seems to be specific for PrP. In this context, it is tempting to speculate that this ability might be linked to the unique feature of PrPΔC to convert into PrPΔC.

The N-terminal Domain of Sho Can Functionally Replace That of PrP—Our study emphasized a similar activity of Sho and PrP to protect cells against excitotoxin- and PrPΔHD-induced toxicity and revealed a crucial role for the N-terminal domain proximal to the HD. Both PrPΔN and ShoΔN showed a significantly reduced stress-protective activity. To address the possibility that both proteins interact with similar co-factors through their N termini, we fused the N-terminal domain of Sho to PrPΔN. The chimeric protein N-ShoPrP-C had a stress-protective activity similar to that of WT Sho or WT PrP, indicating that the N-terminal domain of Sho could functionally replace that of PrP. There is neither sequence homology between the N-terminal domains of Sho and PrP nor an indication that the N-terminal domain of Sho is able to bind copper. The only similarity seems to be that both domains are intrinsically disordered. Based on the idea that intrinsically disordered domains are involved in protein-protein interactions, it appears plausible to assume that the N-terminal domain of PrP and Sho mediates interaction with the same co-receptor, required for stress-protective signaling. Further studies are now required to identify the putative co-receptor and signaling pathway(s) activated by PrP and Sho.

Acknowledgments—We thank Ulrike Resenberger for critical reading of the manuscript and Veronika Müller for technical help.

REFERENCES

1. Collinge, J. (2001) Annu. Rev. Neurosci. 24, 519–550
2. Prusiner, S. B., Scott, M. R., DeArmond, S. J., and Cohen, F. E. (1998) Cell 93, 337–348
3. Weissmann, C., Fischer, M., Raeder, A., Büeler, H., Sailer, A., Shmerling, D., Rülicke, T., Brandner, S., and Aguzzi, A. (1996) Cold Spring Harb. Symp. Quant. Biol. 61, 511–522
4. Chesebro, B. (2003) Br. Med. Bull. 66, 1–20
5. Büeler, H., Aguzzi, A., Sailer, A., Greiner, R. A., Autenried, P., Aguett, M., and Weissmann, C. (1993) Cell 73, 1339–1347
6. Brandner, S., Isenmann, S., Raeder, A., Fischer, M., Sailer, A., Kobayashi, Y., Marino, S., Weissmann, C., and Aguzzi, A. (1996) Nature 379, 339–343
7. Mallucci, G., Dickinson, A., Linehan, J., Klöhn, P. C., Brandner, S., and Collinge, J. (2003) Science 302, 871–874
8. Chesebro, B., Treefio, M., Race, R., Meade-White, K., Tonna-DeMasi, M., Fersko, R., Raymond, L., Favara, C., Baron, G., Priola, S., Caughhey, R., Masliah, E., and Oldstone, M. (2005) Science 308, 1435–1439
9. Rambold, A. S., Müller, V., Ron, U., Ben-Tal, N., Winkhofer, K. F., and Tatzelt, J. (2008) EMBO J. 27, 1974–1984
10. Donné, D. G., Viles, J. H., Groth, D., Mehlhorn, I., James, T. L., Cohen, F. E., Prusiner, S. B., Wright, P. E., and Dyson, H. J. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 13452–13457
11. Riek, R., Hornermann, S., Wider, G., Billetter, M., Glockshuber, R., and Wüthrich, K. (1996) Nature 382, 180–182
12. Riek, R., Hornermann, S., Wider, G., Glockshuber, R., and Wüthrich, K. (1997) FEBS Lett. 413, 282–288
13. Tatzelt, J., and Winkhofer, K. F. (2004) Amyloid 11, 162–172
14. Fischer, M., Rülicke, T., Raeder, A., Sailer, A., Moser, M., Oesch, B., Brandner, S., Aguzzi, A., and Weissmann, C. (1996) EMBO J. 15, 1255–1264
15. Mitteregger, G., Vosko, M., Krebs, B., Xiang, W., Kohlmannsperger, V., Nölting, S., Hamann, G. F., and Kretzschmar, H. A. (2007) Brain Pathol. 17, 174–183
16. Winkhofer, K. F., Tatzelt, J., and Haass, C. (2008) EMBO J. 27, 336–349
17. Shmerling, D., Hegyi, I., Fischer, M., Blättler, T., Brandner, S., Götz, J., Rülicke, T., Flechsig, E., Cozio, A., von Mering, C., Hangartner, C., Aguzzi, A., and Weissmann, C. (1998) Cell 93, 203–214
18. Baumann, F., Tornay, M., Brabec, B., Pahnke, J., Kloz, U., Niemann, H. H., Heidenkeller, M., Rülicke, T., Bärkle, A., and Aguzzi, A. (2007) EMBO J. 26, 538–547
19. Liu, A., Christensen, H. M., Stewart, L. R., Roth, K. A., Chiesa, R., and Harris, D. A. (2007) EMBO J. 26, 548–558
20. Winkhofer, K. F., Hesse, J., Keller, U., Reintjes, A., Muranyi, W., Moarefi, I., and Tatzelt, J. (2003) J. Biol. Chem. 278, 14961–14970
21. Westergard, L., Christensen, H. M., and Harris, D. A. (2007) Biochim. Biophys. Acta 1772, 629–644
22. Premzl, M., Sangiorgio, L., Strumbo, B., Marshall Graves, J. A., Simonic, T., and Gready, I. E. (2003) Gene 314, 89–102
23. Miesbauer, M., Tomaka, M., Riemer, C., Oidtmann, B., Winkhofer, K. F., Baier, M., and Tatzelt, J. (2006) Biochem. Biophys. Res. Commun. 341, 218–224
24. Watts, J. C., Drisaldi, B., Ng, V., Yang, J., Strome, B., Horne, P., Sy, M. S., Yoong, L., Young, R., Mastrangelo, P., Bergeron, C., Fraser, P. E., Carlson, G. A., Mount, H. T., Schmitt-Ulms, G., and Westaway, D. (2007) EMBO J. 26, 4038–4050
25. Kascak, R. J., Rubenstein, R., Merz, P. A., Tonna-DeMasi, M., Fersko, R., Carp, R. I., Wisniewski, H. M., and Diringer, H. (1987) J. Virol. 61, 3688–3693
26. Kiachopoulos, S., Bracher, A., Winkhofer, K. F., and Tatzelt, J. (2005) J. Biol. Chem. 280, 9320–9329
27. Rambold, A. S., Miesbauer, M., Rapaport, D., Bartke, T., Baier, M., Winkhofer, K. F., and Tatzelt, J. (2006) Mol. Biol. Cell 17, 3356–3368
28. Van den Brulle, J., Fischer, M., Langmann, T., Horn, G., Waldmann, T., Arnold, S., Fuhrmann, M., Schatz, O., O’Connell, T., O’Connell, D., Auckenthaler, A., and Schwer, H. (2008) BioTechniques 45, 340–343
29. Winkhofer, K. F., and Tatzelt, J. (2000) Biochim. Biophys. Acta 1439–1433
30. Tompa, P., Fuxreiter, M., Oldfield, C. J., Simon, I., Dunker, A. K., and Uversky, V. N. (2009) Bioessays 31, 328–335